Abstract
Background: Increasing evidence suggests that glycemic control is necessary but insufficient to alter cardiovascular complications in Type 2 DM. Glucagon like peptide-1(GLP-1) is a novel anti-glycemic agent that possesses both insulinotropic and insulinomimetic actions and has been shown to be cardio-protective in both animals and humans. However, it is uncertain as to whether the protective effects are mediated by the native peptide, GLP-1(7-36) or its active metabolite, GLP-1(9-36). The goal of the present study was to determine the effects of GLP-1 (7-36) versus GLP-1(9-36) on post-ischemic contractile dysfunction.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have